Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals, Inc. (PHAT)
:PHAT
PHAT Stock Chart & Stats
$14.41
-$0.22(-3.06%)
At close: 4:00 PM EST
$14.41
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$2.21 - $16.08
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.15M
Market Cap
$1.04B
Enterprise Value$1.31B
Total Cash (Recent Filing)$135.16M
Total Debt (Recent Filing)$2.71M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Mar 03, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding71,138,440
10 Day Avg. Volume924,044
30 Day Avg. Volume1,148,749
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-2.02
Price to Sales (P/S)9.28
P/FCF Ratio-1.92
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue8.91
Enterprise Value/Gross Profit10.22
Enterprise Value/Ebitda-6.44
Forecast
1Y Price Target
$27.67Price Target Upside92.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.11
Revenue Forecast (FY)$170.39M
Bulls Say, Bears Say
Bulls Say
Operating ExpensesThe company effectively reduced operating expenses by 43% quarter over quarter, indicating successful commercial restructuring.
Prescription GrowthConsistent growth in filled VOQUEZNA prescriptions, with a 28% increase over the previous quarter, highlights effective commercial execution.
Revenue PerformancePHAT reported $49.5M in 3Q25 VOQUEZNA revenue, above the FactSet consensus of $47.0M.
Bears Say
Insurance Coverage IssuesConcerns exist over prescriptions being written but not filled due to potential insurance coverage issues and patient follow-up challenges.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals, Inc.’s price range in the past 12 months?
Phathom Pharmaceuticals, Inc. lowest stock price was $2.21 and its highest was $16.08 in the past 12 months.
What is Phathom Pharmaceuticals, Inc.’s market cap?
Phathom Pharmaceuticals, Inc.’s market cap is $1.04B.
When is Phathom Pharmaceuticals, Inc.’s upcoming earnings report date?
Phathom Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 103 days.
How were Phathom Pharmaceuticals, Inc.’s earnings last quarter?
Phathom Pharmaceuticals, Inc. released its earnings results on Oct 30, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.463 by $0.053.
Is Phathom Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Phathom Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Phathom Pharmaceuticals, Inc. pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
What is Phathom Pharmaceuticals, Inc.’s EPS estimate?
Phathom Pharmaceuticals, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Phathom Pharmaceuticals, Inc. have?
Phathom Pharmaceuticals, Inc. has 71,138,440 shares outstanding.
What happened to Phathom Pharmaceuticals, Inc.’s price movement after its last earnings report?
Phathom Pharmaceuticals, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.463. Following the earnings report the stock price went down -1.626%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PHAT
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.67 (92.02% Upside)
$27.67 (92.02% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 25.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.92%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals (PHAT) is a biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal diseases. The company primarily targets conditions such as peptic ulcer disease and gastroesophageal reflux disease (GERD) with its lead product candidate, Vonoprazan, a novel potassium-competitive acid blocker designed to provide improved efficacy and tolerability compared to traditional therapies. Phathom operates in the pharmaceuticals sector, emphasizing research, development, and potential commercialization of medications that enhance patient outcomes in digestive health.
PHAT Company Deck
PHAT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Phathom Pharmaceuticals had a strong Q3 with significant revenue growth and a substantial reduction in operating expenses and cash usage. The company is effectively executing its gastroenterology-focused strategy. However, there are potential challenges such as the temporary impact of sales force realignment and ongoing uncertainty in TRIPLE PAK supply.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$27.67
▲(92.02% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
11.09% Insiders
10.69% Mutual Funds
50.95% Other Institutional Investors
18.60% Public Companies and
Individual Investors